Sepsis treatment by recombinant histidine-rich glycoprotein

Researchers demonstrated that plasma histidine-rich glycoprotein (HRG) played very important roles; maintaining the quiescence of circulating neutrophils, protecting vascular endothelial cells from excessive activation and pro-thrombotic state, and inhibiting the aggregation of red blood cells. All these effects contribute to anti-septic effects of HRG.

We are now looking for a pharmaceutical company to develop a recombinant HRG (r-HRG) medicine for treatment by using this technology further under the licensing.

Please feel free to contact us if you would like to learn more about this technology.

Inquiry Form

Your Name (*Required)

E-Mail Address (*Required)

Company Name


Following submission of your inquiry

We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.


Our support is provided free of charge.
The information submitted on this form is for business development use only.

About Tech Manage Corp.
Copyright © Tech Manage Corp. All Rights Reserved.